Drugs · Brain health technique
Anti-Tau Monoclonal Antibodies (Emerging)
Evidence grade: Experimental
Investigational biologics designed to block or clear pathological tau aggregates inside neurons, targeting tau propagation rather than extracellular amyloid. Includes semorinemab, gosuranemab, and tilavonemab currently in late-phase trials.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Neuroprotective & Disease-modifying Therapies
- Evidence grade
- Experimental
- Strength of evidence
- Low
How to practice Anti-Tau Monoclonal Antibodies (Emerging)
Only accessible through clinical trials. Candidates typically require tau PET or CSF-confirmed pathology. Participation involves repeated infusions and imaging follow-up. No approved clinical use yet; appropriate for those with biomarker-confirmed early Alzheimer’s or MCI in research settings.
The evidence behind Anti-Tau Monoclonal Antibodies (Emerging)
Tau tangles correlate more closely with cognitive decline than amyloid burden. Early human studies show target engagement but limited measurable benefit so far. Mechanism: antibodies bind extracellular tau fragments, preventing their spread and reducing neurofibrillary tangle formation. Evidence remains early-phase with safety established but efficacy unproven; second-generation molecules are more promising.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.